Celgene completes $7.2 billion acquisition of ReceptosStaff writer ▼ | August 28, 2015
Celgene Corporation announced it has closed its acquisition of Receptos, stockholders received $232 per share in cash, for a total of approximately $7.2 billion, net of cash acquired.
Acquisition $232 per Receptos share in cash
In August, Celgene announced that the applicable waiting period for tender offer expired and that the expiration of the HSR waiting period satisfies one of the conditions to the closing of the acquisition.
As a result of the completion of the merger, the common stock of Receptos is no longer listed for trading on the NASDAQ Global Market or any other exchange and trading ceased at the close of the markets on Thursday, August 27, 2015.
Receptos stockholders who hold shares through a bank or broker will not have to take any action to have their shares converted into cash, since these conversions will be handled by the bank or broker.
Stockholders who hold stock certificates can surrender their certificates for $232 per share in cash, without interest and less any applicable withholding taxes, through the paying agent for the merger, American Stock Transfer & Trust Company, LLC. ■